AdaptHealth Corp. (NASDAQ:AHCO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $14.2857.

AHCO has been the subject of several analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $11.00 price objective on shares of AdaptHealth in a research note on Monday, April 20th. UBS Group lowered their price objective on AdaptHealth from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Canaccord Genuity Group raised their price objective on AdaptHealth from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen raised AdaptHealth from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Finally, Robert W. Baird set a $18.00 price objective on AdaptHealth in a research note on Wednesday, May 6th.

AdaptHealth Stock Performance

Shares of NASDAQ AHCO opened at $10.21 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.71 and a current ratio of 0.92. The company has a market cap of $1.39 billion, a P/E ratio of -16.47, a P/E/G ratio of 0.52 and a beta of 1.47. The firm’s fifty day moving average is $10.82 and its two-hundred day moving average is $10.61. AdaptHealth has a 52-week low of $8.51 and a 52-week high of $13.43.

AdaptHealth (NASDAQ:AHCO) last posted its earnings results on Tuesday, May 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13). AdaptHealth had a positive return on equity of 2.76% and a negative net margin of 2.42%.The business had revenue of $819.80 million during the quarter, compared to the consensus estimate of $796.63 million. During the same quarter last year, the firm earned ($0.05) earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, analysts anticipate that AdaptHealth will post 0.44 EPS for the current fiscal year.

Insider Activity

In related news, insider Russell E. Schuster III sold 11,275 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total transaction of $113,426.50. Following the transaction, the insider directly owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.95% of the stock is owned by insiders.

Hedge Funds Weigh In On AdaptHealth

Several hedge funds have recently added to or reduced their stakes in AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in AdaptHealth by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock valued at $656,000 after purchasing an additional 2,564 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in AdaptHealth by 32.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock valued at $6,192,000 after purchasing an additional 139,828 shares during the last quarter. Woodline Partners LP bought a new position in AdaptHealth during the 1st quarter valued at about $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in AdaptHealth by 18.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock valued at $2,534,000 after purchasing an additional 35,879 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in AdaptHealth by 1.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company’s stock valued at $1,997,000 after purchasing an additional 2,718 shares during the last quarter. 82.67% of the stock is currently owned by institutional investors.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.